Logo

BIOA

BioAge Labs, Inc.

BIOA

BioAge Labs, Inc. • NASDAQ
$9.49 ▲ 1.50% (+0.14)
Market Cap $340.26 M
52w High $20.37
52w Low $2.88
Dividend Yield 0%
P/E 0.7
Volume 104.59K
Outstanding Shares 35.86M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.054M ▼ $25.194M ▼ $-20.171M ▲ -982.035% ▼ $-0.56 ▲ $-19.973M ▲
Q2-2025 $2.412M ▲ $27.183M ▲ $-21.563M ▼ -893.988% ▼ $-0.6 ▼ $-21.304M ▼
Q1-2025 $1.451M ▲ $17.897M ▼ $-12.928M ▲ -890.972% ▼ $-0.36 ▲ $-12.636M ▲
Q4-2024 $0 $25.362M ▲ $-21.129M ▲ 0% $-1.97 ▲ $-20.763M ▲
Q3-2024 $0 $24.75M $-23.407M 0% $-6.7 $-22.981M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $285.778M ▼ $305.09M ▼ $27.626M ▲ $277.464M ▼
Q2-2025 $297.295M ▼ $322.148M ▼ $27.367M ▼ $294.781M ▼
Q1-2025 $320.518M ▼ $343.841M ▼ $30.674M ▼ $313.167M ▼
Q4-2024 $354.349M ▲ $358.234M ▲ $35.107M ▲ $323.127M ▲
Q3-2024 $334.474M $337.381M $23.633M $313.748M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-20.171M ▲ $-16.044M ▲ $12.841M ▲ $-1.544M ▼ $-4.757M ▲ $-16.066M ▲
Q2-2025 $-21.563M ▼ $-19.969M ▼ $-15.641M ▲ $-1.5M $-37.156M ▲ $-20.128M ▼
Q1-2025 $-12.928M ▲ $-17.363M ▼ $-77.988M ▼ $-1.5M ▼ $-96.863M ▼ $-17.789M ▼
Q4-2024 $-21.129M ▲ $-5.138M ▲ $-26K ▲ $24.902M ▼ $19.875M ▼ $-5.164M ▲
Q3-2024 $-23.407M $-14.931M $-305K $190.683M $175.389M $-15.236M

Five-Year Company Overview

Income Statement

Income Statement BioAge is still a pure research company with essentially no product revenue so far. Its costs are mainly research, development, and general overhead, which lead to steady operating and net losses each year. Those losses have crept up over time as the company has invested more into its pipeline, but they are still relatively modest for a biotech. The very large loss per share figures are largely a function of the company’s small pre‑IPO share count rather than a sign of unusually heavy cash burn. Overall, the income statement tells a typical early‑stage biotech story: spending first, revenue likely years away and very dependent on clinical success.

Balance Sheet

Balance Sheet The balance sheet has transformed recently from a thin, slightly stressed profile to a healthier, cash‑rich one. Most of the company’s assets are now held in cash, suggesting a recent capital infusion from the IPO and partnerships. Debt has been kept very low and has even declined, which reduces financial risk. Shareholders’ equity has shifted from negative to clearly positive, closing the earlier capital hole. In simple terms, the company now has a much more solid financial cushion to support its research plans, though it still depends on future financing or deal income over time.

Cash Flow

Cash Flow Cash flows are negative, driven by ongoing research and operating expenses, with no offsetting product inflows yet. The cash burn has been fairly consistent over the past few years, and there is essentially no spending on physical assets, which fits a lean, R&D‑heavy biotech model. This means BioAge is using cash mainly for people, clinical work, and data rather than buildings or equipment. The strengthened cash position buys time, but the business model still relies on periodic capital raises or partnership payments until a drug is approved or licensed on attractive terms.

Competitive Edge

Competitive Edge BioAge operates in a highly competitive space, targeting obesity and metabolic diseases of aging where very large pharmaceutical companies and many biotechs are active. Its main differentiator is access to decades‑long human aging data and the ability to mine that data with advanced analytics, which is difficult for rivals to replicate quickly. Partnerships with major players like Novartis and Eli Lilly provide validation, expertise, and some funding support, which is a meaningful edge for a small company. However, the firm is still early‑stage, with no approved products, and it must compete against incumbents with established obesity drugs and deep commercial capabilities. The competitive position is promising but unproven and will depend heavily on clinical results and deal‑making.

Innovation and R&D

Innovation and R&D Innovation is the core of BioAge’s story. The company’s platform combines long‑term human aging cohorts, multi‑omics data, and machine learning to uncover biological pathways linked to healthy aging and metabolic disease. This data‑first approach can, in principle, generate a steady stream of novel targets. The lead program, a brain‑penetrant NLRP3 inhibitor for obesity (BGE‑102), aims to tackle inflammatory and neurological aspects of weight regulation and may pair well with existing GLP‑1 drugs. The next‑generation APJ agonist program reflects a deliberate pivot after discontinuing an earlier candidate due to safety concerns, showing both the risks of R&D and the company’s willingness to adapt based on data. Ongoing work with external biobanks further enlarges its discovery engine. Overall, R&D is high‑risk but strategically focused and increasingly diversified within the metabolic aging theme.

Summary

BioAge is a very early‑stage, pre‑revenue biotech whose value currently rests far more on its scientific platform, pipeline potential, and partnerships than on traditional financial metrics. The income statement shows controlled but persistent losses typical of a company investing ahead of any commercial returns. The balance sheet now looks much healthier, with strong cash, low debt, and positive equity, giving it room to pursue its programs. Cash flows remain negative and will continue that way until either a major partnership, licensing deal, or eventual product launch materializes. Competitively, the firm’s unique longitudinal human data, AI‑driven discovery, and big‑pharma alliances offer real differentiation, but it operates in one of the most competitive and fast‑moving segments of healthcare. The innovation engine and obesity‑focused pipeline create significant upside potential but are coupled with substantial clinical, regulatory, and funding uncertainty. Going forward, the most important signals will be clinical data from the lead program, progress on next‑generation candidates, and the company’s ability to convert its discovery platform and partnerships into long‑term, sustainable value.

NEWS

November 25, 2025 · 4:30 PM UTC

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

Read more

November 7, 2025 · 9:00 AM UTC

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

Read more

October 2, 2025 · 7:27 AM UTC

BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Read more

September 15, 2025 · 9:30 AM UTC

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

Read more